TransCode regains Nasdaq equity compliance; still faces bid price rule non-compliance with May 6 deadline

Transcode Therapeutics, Inc.

Nasdaq determined TransCode met minimum $2.5M stockholders' equity requirement for continued listing.
Company placed on mandatory panel monitor through January 26, 2025, subject to delisting if non-compliant again.
Separately, TransCode remains non-compliant with minimum $1.00 bid price rule; must cure by May 6, 2024.
Failure to meet bid price rule could lead to additional 180-day compliance period if other listing standards are met.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.